Evidence map›Paper›PMID 35869577›Full record

ArticleCytopathology : official journal of the British Society for Clinical Cytology2022

Performance of breast fine needle aspiration as an initial diagnostic tool: A large academic hospital experience.

Zhengshan Chen, Christine Salibay, Wafaa Elatre, Wesley Y Naritoku, Yanling Ma, Sue Ellen Martin, Tiannan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytopathology : official journal of the British Society for Clinical Cytology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Performance of breast fine needle aspiration as an initial diagnostic tool: A large academic hospital experience.Cytopathology : official journal of the British Society for Clinical Cytology · 2022
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhengshan ChenDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.
Christine SalibayDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.
Wafaa ElatreDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.
Wesley Y NaritokuDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.
Yanling MaDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.
Sue Ellen MartinDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.
Tiannan WangDepartment of Pathology and Laboratory Medicine, University of Southern California/LAC-USC Medical Center, Los Angeles, California, USA.ORCID 0000-0002-2983-7168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical performance of the Yokohama reporting system for breast cytology remains uncertain.

methodsIn this study, we retrospectively evaluated 318 breast fine needle aspirations (FNABs) from Los Angeles County Hospital over a five-year period, analysing data for breast cytology, histology, and radiology.

resultsAmong 318 breast FNAB cases, 78.3% (249/318) were benign and 5.3% (17/318) malignant. Of 83 cases with follow-up histology, 14.5% (12/83) were insufficient, 66.3% (55/83) were benign, and 16.9% (17/83) were malignant. Of 55 benign cases, 61.8% (34/55) were fibroadenoma and 9 (9/55, 16.4%) were fibrocystic changes. Two cases were diagnosed as "atypical" but confirmed "benign" on core needle biopsy (CNB). No "suspicious" cases were found. Seventeen malignant cases were confirmed by CNB, including 70.6% (12/17) invasive ductal carcinoma, 11.8% (2/17) invasive lobular carcinoma, and one malignant phyllodes tumour. Receptor studies on cell blocks of three malignant cases showed concordant results with CNB results. In addition, 82.2% (148/180) of lesions with Breast Imaging-Reporting and Data System (BI-RADS) scores of 2 or 3 were benign and 92.3% (12/13) BI-RADS score 5 lesions were malignant on FNAB. Finally, 90% (67/74) of BI-RADS 4a lesions were benign, and 97% (36/37) of fibroadenomas were BI-RADS score 4a.

conclusionThis, by far the largest U.S. breast cytology study, showed 93.3% sensitivity, 100% specificity, 100% positive predictive value, and 98.2% negative predictive value for breast FNAB. Women with breast lesions of BI-RADS score 3 or less have a low risk of malignancy; FNAB would contribute to the reduction of excisional biopsies. FNAB can be considered as an initial diagnostic tool for BI-RADS 4 mass/lesions and satellite lesions, as well as for triaging patients.

Indexed as

Breast NeoplasmsFibroadenomaBiopsy, Fine-NeedleBreastFemaleHospitalsHumansHypertrophyRetrospective StudiesSensitivity and Specificityand radiology correlationBreast cytologycytologyfine needle aspirationhistology

Identifiers

PMID35869577
PMCPMC9826159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.